NALIDIXIC ACID SODIUM

Nalidixic acid sodium is a sodium salt form of nalidixic acid with similar quinolone activity against gram‑negative pathogens. It is used in oral formulations for urinary infections. Benefits and antibacterial spectrum mirror the parent compound. Side effects include nausea, vomiting, dizziness, headache, photosensitivity, and rare allergic or hematologic reactions.

SKU: 7cd3af1335f5 Category: Tag:

Product Description


Mechanism of Action

NALIDIXIC ACID SODIUM (ID 26819) exhibits a multi‑vector biochemical action pattern, influencing enzymatic cascades, receptor‑mediated signalling, intracellular ion behaviour, mitochondrial oxidative dynamics and transcriptional regulatory networks. Its structural characteristics suggest interaction with catalytic residues, allosteric pockets and regulatory scaffolds, enabling modulation of phosphorylation circuits, second‑messenger systems (cAMP, Ca²⁺, IP₃), ROS generation, membrane polarization and metabolic‑flux channeling.

Depending on biological context, NALIDIXIC ACID SODIUM may alter mitochondrial membrane potential, redox buffering capacity, calcium sequestration, cytoskeletal integrity, vesicle trafficking efficiency and transcription‑factor activation, resulting in broad mechanistic adaptability across experimental systems.

Benefits and Advantages

This compound is highly valued in advanced biochemical and pharmacological research frameworks, including:

  • High‑resolution receptor–ligand mapping and affinity prediction
  • Enzyme‑kinetic profiling and catalytic‑pathway deconstruction
  • Mitochondrial‑stress testing, ATP‑flux analysis and ROS‑equilibrium studies
  • Integrated multi‑omics research: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal modelling involving actin/tubulin regulation
  • Apoptosis, autophagy, necroptosis and ferroptosis signalling investigations
  • Structure–activity relationship (SAR) exploration and molecular optimisation
  • Pharmacodynamic simulations for mechanistic threshold and dose‑response studies

Side Effects and Risks

Possible laboratory‑observed risks include:

  • Redox imbalance with elevated ROS levels
  • Mitochondrial overactivation or respiratory‑chain suppression
  • Ion‑channel dysregulation affecting Na⁺/K⁺/Ca²⁺ flow
  • Cross‑activation or inhibition of unintended receptor systems
  • Cytoskeletal destabilisation and impaired membrane integrity
  • Dose‑dependent cytotoxicity or induction of apoptotic/autophagic pathways
  • Transcriptional instability and activation of inflammatory cascades (NF‑κB, JNK, p38)

Strict biosafety handling, controlled dosing and regulated environmental conditions are required for all experimental use. Not intended for human or veterinary application.

Datasheet


Molecular Formula

C12H11N2NaO3

Molecular Weight

254.22 g/mol

CAS Number

538497

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Sodium nalidixate; Nalidixate sodium anhydrous; Y7NU182221; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-, sodium salt; RefChem:831698

IUPAC/Chemical Name

sodium 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylate

InChl Key

ROKRAUFZFDQWLE-UHFFFAOYSA-M

InChl Code

InChI=1S/C12H12N2O3.Na/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14;/h4-6H,3H2,1-2H3,(H,16,17);/q;+1/p-1

References

https://pubchem.ncbi.nlm.nih.gov/compound/3864541;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download